Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rapidly dividing immune cells are primarily activated lymphocytes (T and B cells) undergoing clonal expansion in response to antigen stimulation. This rapid proliferation is essential for mounting an effective adaptive immune response. Key mechanisms involve upregulation of transcription factors like c-Myc, driving cell cycle progression and metabolic changes necessary for rapid division. While vital for pathogen clearance and immunological memory, uncontrolled proliferation can lead to autoimmunity or malignancy. Targeting these cells is relevant for immunosuppression, autoimmune disease therapy, and cancer immunotherapy modulation.
Varies depending on the specific drug and targeted pathway. Examples include: inhibition of T cell activation, inhibition of DNA synthesis, and induction of cell death.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rapidly Dividing Immune Cells (N/A).